# MaxCyte

Type: Company (MXCT)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/maxcyte
Canonical HTML page: https://getbiobrief.com/entity/maxcyte

## Recent coverage (1 stories)

### MaxCyte Faces 2026 Headwinds Amid Cell Therapy Sector Rationalization
2026-03-25 00:44:26 · Sentiment: Positive · Impact: 7/10 · Sources: 2

MaxCyte reported a 15% revenue decline for 2025, driven by the loss of six clinical programs and reduced spending from its largest customer. Despite these headwinds, the company improved gross margins to 78% and expanded its installed base to 857 instruments, signaling long-term platform persistence.
Full story: https://getbiobrief.com/story/maxcyte-q4-2025-earnings-analysis-cell-therapy-headwinds

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.